Legal & General Group PLC Black Diamond Therapeutics, Inc. Transaction History
Legal & General Group PLC
- $368 Billion
- Q4 2024
A detailed history of Legal & General Group PLC transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 3,825 shares of BDTX stock, worth $6,273. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,825
Previous 3,825
-0.0%
Holding current value
$6,273
Previous $16,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding BDTX
# of Institutions
94Shares Held
47.6MCall Options Held
2.9KPut Options Held
69.4K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.5MShares$17.2 Million0.01% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.52MShares$14 Million0.36% of portfolio
-
Vestal Point Capital, LP New York, NY5.6MShares$9.18 Million0.71% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$7.3 Million0.68% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$5.28 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $59.6M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...